Search results for: ripretinib

Home/Search: ripretinib
22 06, 2020

Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor

By |2020-06-22T09:47:31-04:00June 22nd, 2020|Drug Treatment, News, Qinlock|

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.

17 06, 2020

QINLOCK (ripretinib) – aprobado como cuarta línea de tratamiento para GIST

By |2020-06-17T11:29:18-04:00June 17th, 2020|Drug Treatment, Global, News, Qinlock|

La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.

18 05, 2020

FDA Approves QINLOCK (ripretinib) by Deciphera for 4L GIST Patients

By |2020-06-17T11:30:36-04:00May 18th, 2020|Clinical Trials, News|

The FDA approved QINLOCKTM (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST.

14 02, 2020

Priority Review Granted for Ripretinib

By |2020-02-14T09:57:21-05:00February 14th, 2020|Drug Treatment, News|

Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).

14 08, 2019

Deciphera Releases Positive Trial Results for Ripretinib

By |2019-08-14T09:38:14-04:00August 14th, 2019|Drug Treatment, News, Research|

Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have also updated results from the Phase 1 Study. Deciphera shared that "patients treated [...]

2 02, 2023

Progress in Precision Medicine for GIST Patients

By |2023-02-02T14:37:45-05:00February 2nd, 2023|Clinical Trials, Drug Treatment, News|

These new data were presented by Dr. Sebastian Bauer and Dr. Breelyn A. Wilky during the 2023 January ASCO Plenary Series from the INTRIGUE Efficacy Results of ctDNA Analysis for GIST Patients.

4 01, 2023

Deciphera Announces New Results from Analysis from Intrigue Study

By |2023-01-04T11:40:28-05:00January 4th, 2023|News, Qinlock|

Deciphera issued a press release today sharing the results of an exploratory analysis of data using circulating tumor DNA (ctDNA) from the INTRIGUE Phase 3 clinical study of ripretinib and announcing plans to initiate INSIGHT.

Need a new search?

If you didn't find what you were looking for, try a new search!

Go to Top